A nonrandomized, phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Lymphoma, Large-Cell, Anaplastic
  • Receptor Protein-Tyrosine Kinases

abstract

  • Sequential irinotecan and flavopiridol are ineffective and poorly tolerated in patients with advanced HCC. Despite our limited assessments, it is possible that the presence of wild-type p53 is necessary but not sufficient to predict response in HCC.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

PubMed ID

  • 23293699

Additional Document Info

start page

  • 185

end page

  • 9

volume

  • 5

number

  • 6